PSW001

PSW001 is a small molecule therapeutic candidate being developed by Parkure Ltd. for the treatment of Parkinson's disease. Parkure utilizes a specialized drug discovery platform that employs *Drosophila* (fruit fly) models of Parkinson's disease to screen for compounds capable of rescuing disease phenotypes. While specific details regarding the molecular target and mechanism of action for PSW001 have not been publicly disclosed, the drug is part of a pipeline focused on neurodegenerative, endocrine, and metabolic conditions. It is currently in the early stages of development, often categorized as having a 'Pending' status in pharmaceutical databases, indicating it is in the discovery or preclinical pipeline awaiting further regulatory classification.